Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuo Touyama

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Kyobu Geka. the Japanese Journal of Thoracic Surgery|April 21, 2024
[Video-assisted Thoracoscopic Surgery for Chest Trauma]Osamu Kakazu, Morio Ohta, Tetsuo Touyama
Kyobu Geka. the Japanese Journal of Thoracic Surgery|July 20, 2023
[Three-dimensional and 4K Three-dimensional Uniportal Video-assisted Thoracoscopic Surgery for Mediastinal and Chest Wall Disease During Respiratory Surgery]Morio Ohta, Osamu Kakazu, Tetsuo Touyama
Kyobu Geka. the Japanese Journal of Thoracic Surgery|October 2, 2012
[Single-incision thoracoscopic surgery( SITS) for mediastinal disease]Morio Ohta, Osamu Kakazu, Tetsuo Touyama, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|December 8, 2021
[Palmar Hyperhidrosis Associated with the Azygos Lobe]Osamu Kakazu, Morio Ohta, Tomonari Shiohira, et al.
World Journal of Surgery|March 31, 2010
Partial breast reconstruction for an inferomedial breast carcinoma using an omental flapHisamitsu Zaha, Hiroki Sunagawa, Kouji Kawakami, et al.
International Journal of Clinical Oncology|July 6, 2016
Erratum to: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancerYoshinori Miyata, Tetsuo Touyama, Takaya Kusumi, et al.
International Journal of Clinical Oncology|December 30, 2015
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancerYoshinori Miyata, Tetsuo Touyama, Takaya Kusumi, et al.
International Journal of Clinical Oncology|September 5, 2015
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)Yutaka Ogata, Mototsugu Shimokawa, Takaho Tanaka, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2015
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)Masahito Kotaka, Takayuki Yoshino, Koji Oba, et al.
International Journal of Clinical Oncology|June 4, 2015
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)Keisuke Miwa, Eiji Oki, Yasunori Emi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Kyobu Geka. the Japanese Journal of Thoracic Surgery|April 21, 2024
[Video-assisted Thoracoscopic Surgery for Chest Trauma]Osamu Kakazu, Morio Ohta, Tetsuo Touyama
Kyobu Geka. the Japanese Journal of Thoracic Surgery|July 20, 2023
[Three-dimensional and 4K Three-dimensional Uniportal Video-assisted Thoracoscopic Surgery for Mediastinal and Chest Wall Disease During Respiratory Surgery]Morio Ohta, Osamu Kakazu, Tetsuo Touyama
Kyobu Geka. the Japanese Journal of Thoracic Surgery|October 2, 2012
[Single-incision thoracoscopic surgery( SITS) for mediastinal disease]Morio Ohta, Osamu Kakazu, Tetsuo Touyama, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|December 8, 2021
[Palmar Hyperhidrosis Associated with the Azygos Lobe]Osamu Kakazu, Morio Ohta, Tomonari Shiohira, et al.
World Journal of Surgery|March 31, 2010
Partial breast reconstruction for an inferomedial breast carcinoma using an omental flapHisamitsu Zaha, Hiroki Sunagawa, Kouji Kawakami, et al.
International Journal of Clinical Oncology|July 6, 2016
Erratum to: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancerYoshinori Miyata, Tetsuo Touyama, Takaya Kusumi, et al.
International Journal of Clinical Oncology|December 30, 2015
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancerYoshinori Miyata, Tetsuo Touyama, Takaya Kusumi, et al.
International Journal of Clinical Oncology|September 5, 2015
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)Yutaka Ogata, Mototsugu Shimokawa, Takaho Tanaka, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2015
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)Masahito Kotaka, Takayuki Yoshino, Koji Oba, et al.
International Journal of Clinical Oncology|June 4, 2015
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)Keisuke Miwa, Eiji Oki, Yasunori Emi, et al.
Pageof 2